Clinical efficacy of Danggui Sini Decoction for treatment of lower limb arteriosclerosis obliterans: A randomized...

Endovascular revascularization for lower limb arteriosclerosis obliterans (ASO) is often limited by long-term restenosis. This study evaluated whether the traditional Chinese medicine formula Danggui Sini Decoction (DGSD) could improve mid-term outcomes when combined with the standard procedure.

To investigate the clinical efficacy of DGSD combined with endovascular revascularization in the treatment of ASO and its impact on patients' quality of life.

A total of 38 ASO patients treated at Zhangjiajie People's Hospital from January 2023 to January 2025 were selected and randomly divided into a control group and an experimental group, with 19 patients in each group. The control group received conventional endovascular revascularization and basic treatment, while the experimental group was treated with DGSD in addition to the control group's treatment. The clinical effectiveness rate, freedom from clinically driven target lesion revascularization, primary patency rate, and quality of life scores were compared between the two groups.

Within one month postoperatively, there was no significant difference in clinical effectiveness between the two groups (experimental group: 78.95% vs control group: 84.21%, P > 0.05), but the improvement in quality of life scores in the experimental group was significantly better than that of the control group (P < 0.05). At six months postoperatively, the clinical effectiveness rate in the experimental group was significantly higher than that of the control group (94.74% vs 73.68%, P < 0.05). The experimental group had a higher rate of freedom from clinically driven target lesion revascularization compared to the control group, but the difference was not statistically significant (100% vs 84.21%, P > 0.05). The primary patency rate in the experimental group was significantly better than that of the control group (P < 0.05).

DGSD combined with endovascular revascularization can significantly improve the mid-term clinical efficacy in ASO patients, reduce the risk of lower limb arterial re-occlusion, and enhance quality of life, demonstrating significant clinical application value.